14 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34555645 | Cytokines and chemokines systemic levels are related to dialysis adequacy and creatinine clearance in patients with end-stage renal disease undergoing hemodialysis. | 2021 Nov | 3 |
2 | 31442679 | Evidence for interactions between inflammatory markers and renin-angiotensin system molecules in the occurrence of albuminuria in children with sickle cell anemia. | 2020 Jan | 2 |
3 | 32047847 | Technical Considerations and Confounders for Urine CXCL10 Chemokine Measurement. | 2020 Jan | 3 |
4 | 32342614 | Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. | 2020 Dec | 1 |
5 | 30974283 | Elevated serum CXCL10 in patients with Clostridium difficile infection are associated with disease severity. | 2019 Jul | 1 |
6 | 31277459 | BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine. | 2019 Jul 4 | 3 |
7 | 31285802 | Urinary CXCL9 and CXCL10 Levels and Acute Renal Graft Rejection. | 2019 | 1 |
8 | 29048741 | Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. | 2018 Mar | 1 |
9 | 27548845 | Six-Month Urinary CCL2 and CXCL10 Levels Predict Long-term Renal Allograft Outcome. | 2016 Sep | 1 |
10 | 25222013 | Elevated urinary CXCL10-to-creatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation. | 2015 Apr | 1 |
11 | 25948873 | Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. | 2015 Nov | 2 |
12 | 21876477 | Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. | 2011 Oct 27 | 2 |
13 | 16572110 | Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. | 2006 May | 1 |
14 | 16130407 | [Elevated plasma concentration of IP-10 in patients with type 2 diabetes mellitus]. | 2005 | 1 |